What is CHGCY stock price today?

CHGCY (Chugai Pharmaceutical Co Ltd ADR) stock is trading at $32.11 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CHGCY stock going up or down today?

CHGCY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CHGCY stock now?

The decision to buy CHGCY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CHGCY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CHGCY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CHGCY stock overvalued or undervalued?

CHGCY currently trades at a P/E ratio of 35.73, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if CHGCY is fairly priced.

What is CHGCY's P/E ratio?

CHGCY has a price-to-earnings (P/E) ratio of 35.73, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is CHGCY's market cap?

CHGCY (Chugai Pharmaceutical Co Ltd ADR) has a market capitalization of $101.69 billion, making it a mid-cap stock.

What is CHGCY's price to book ratio?

CHGCY trades at a price-to-book (P/B) ratio of 7.59, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CHGCY pay dividends?

Yes, CHGCY pays dividends with a current yield of 0.02%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is CHGCY's dividend yield?

CHGCY's dividend yield is 0.02%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is CHGCY stock a good long-term investment?

CHGCY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CHGCY's revenue growth rate?

CHGCY has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, CHGCY is profitable with a profit margin of 0.3%. This indicates the company generates 0.3 cents of profit for every dollar of revenue.

What are the risks of investing in CHGCY?

Key risks for CHGCY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CHGCY compare to its competitors?

Compare CHGCY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CHGCY's performance and positioning.

What is CHGCY's stock price target for 2026?

Our AI model provides price targets for CHGCY based on fundamental analysis: Bull case $41.74 (+30%), Base case $36.93 (+15%), Bear case $28.90 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CHGCY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CHGCY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CHGCY's next earnings report?

CHGCY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CHGCY - Chugai Pharmaceutical Co Ltd ADR

NYSE * Healthcare * Drug Manufacturers - General

$32.11

+$1.38 (+4.49%)

About Chugai Pharmaceutical Co Ltd ADR

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

CHGCY Key Statistics

Market Cap

$101.69B

P/E Ratio

35.73

P/B Ratio

7.59

EPS

$0.86

Dividend Yield

0.02%

Revenue Growth

+0.1%

Profit Margin

0.3%

Employees

7,872

How CHGCY Compares to Peers

CHGCY has the highest profit margins in Drug Manufacturers - General

CHGCY ranks 2nd in revenue growth vs peers

CHGCY is the smallest among peers, which may offer higher growth potential

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CHGCY(This stock)	$101.69B	35.7	0%	0.3%	-
LLYEli Lilly	$809.09B	39.3	0%	0.3%	vs LLY
JNJJohnson &	$575.17B	21.8	0%	0.2%	vs JNJ
PFEPfizer Inc	$154.67B	20.0	-0%	0.1%	vs PFE
MRKMerck &	$291.50B	16.2	0%	0.3%	vs MRK
ABBVAbbvie Inc	$368.65B	87.6	0%	0.1%	vs ABBV

Chugai Pharmaceutical Co Ltd ADR Company Information

Headquarters: Nihonbashi Mitsui Tower, Chuo, Japan, 103-8324, undefined
Website: www.chugai-pharm.co.jp
Sector: Healthcare
Industry: Drug Manufacturers - General

About Chugai Pharmaceutical Co Ltd ADR

CHGCY Key Statistics

How CHGCY Compares to Peers

Chugai Pharmaceutical Co Ltd ADR Company Information

Upcoming Events for CHGCY